vs

Side-by-side financial comparison of Editas Medicine, Inc. (EDIT) and STEM, INC. (STEM). Click either name above to swap in a different company.

STEM, INC. is the larger business by last-quarter revenue ($47.1M vs $24.7M, roughly 1.9× Editas Medicine, Inc.). Editas Medicine, Inc. runs the higher net margin — -22.7% vs -33.9%, a 11.2% gap on every dollar of revenue. On growth, STEM, INC. posted the faster year-over-year revenue change (-15.6% vs -19.2%). Over the past eight quarters, Editas Medicine, Inc.'s revenue compounded faster (366.9% CAGR vs 36.1%).

Editas Medicine, Inc.,, is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.

StemCells, Inc. is a public biopharmaceutical company headquartered in Newark, California, that is developing purified human neural stem cells (HuCNS-SCs) in the hopes of treating central nervous system disorders and paralysis. StemCells' HuCNS-SCs have the ability to differentiate into the three main types of cells found in the central nervous system: neurons, astrocytes and oligodendrocytes.

EDIT vs STEM — Head-to-Head

Bigger by revenue
STEM
STEM
1.9× larger
STEM
$47.1M
$24.7M
EDIT
Growing faster (revenue YoY)
STEM
STEM
+3.6% gap
STEM
-15.6%
-19.2%
EDIT
Higher net margin
EDIT
EDIT
11.2% more per $
EDIT
-22.7%
-33.9%
STEM
Faster 2-yr revenue CAGR
EDIT
EDIT
Annualised
EDIT
366.9%
36.1%
STEM

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
EDIT
EDIT
STEM
STEM
Revenue
$24.7M
$47.1M
Net Profit
$-5.6M
$-16.0M
Gross Margin
48.9%
Operating Margin
-31.3%
-17.7%
Net Margin
-22.7%
-33.9%
Revenue YoY
-19.2%
-15.6%
Net Profit YoY
87.6%
68.8%
EPS (diluted)
$0.03
$-4.40

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EDIT
EDIT
STEM
STEM
Q4 25
$24.7M
$47.1M
Q3 25
$7.5M
$38.2M
Q2 25
$3.6M
$38.4M
Q1 25
$4.7M
$32.5M
Q4 24
$30.6M
$55.8M
Q3 24
$61.0K
$29.3M
Q2 24
$513.0K
$34.0M
Q1 24
$1.1M
$25.5M
Net Profit
EDIT
EDIT
STEM
STEM
Q4 25
$-5.6M
$-16.0M
Q3 25
$-25.1M
$-23.8M
Q2 25
$-53.2M
$202.5M
Q1 25
$-76.1M
$-25.0M
Q4 24
$-45.4M
$-51.1M
Q3 24
$-62.1M
$-148.3M
Q2 24
$-67.6M
$-582.3M
Q1 24
$-62.0M
$-72.3M
Gross Margin
EDIT
EDIT
STEM
STEM
Q4 25
48.9%
Q3 25
35.5%
Q2 25
33.4%
Q1 25
32.4%
Q4 24
-4.4%
Q3 24
21.2%
Q2 24
27.6%
Q1 24
-95.0%
Operating Margin
EDIT
EDIT
STEM
STEM
Q4 25
-31.3%
-17.7%
Q3 25
-325.4%
-33.6%
Q2 25
-1440.6%
-34.8%
Q1 25
-1635.1%
-65.0%
Q4 24
-152.2%
-84.4%
Q3 24
-107649.2%
-493.2%
Q2 24
-14016.2%
-1705.5%
Q1 24
-5902.3%
-267.0%
Net Margin
EDIT
EDIT
STEM
STEM
Q4 25
-22.7%
-33.9%
Q3 25
-333.0%
-62.2%
Q2 25
-1487.8%
527.8%
Q1 25
-1633.5%
-76.9%
Q4 24
-148.3%
-91.6%
Q3 24
-101870.5%
-506.3%
Q2 24
-13178.8%
-1712.6%
Q1 24
-5458.1%
-283.9%
EPS (diluted)
EDIT
EDIT
STEM
STEM
Q4 25
$0.03
$-4.40
Q3 25
$-0.28
$-2.84
Q2 25
$-0.63
$-1.79
Q1 25
$-0.92
$-0.15
Q4 24
$-0.55
$-15.29
Q3 24
$-0.75
$-18.24
Q2 24
$-0.82
$-71.81
Q1 24
$-0.76
$-0.46

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EDIT
EDIT
STEM
STEM
Cash + ST InvestmentsLiquidity on hand
$146.6M
$48.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$27.3M
$-249.4M
Total Assets
$186.5M
$308.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EDIT
EDIT
STEM
STEM
Q4 25
$146.6M
$48.9M
Q3 25
$165.6M
$43.1M
Q2 25
$178.5M
$40.8M
Q1 25
$221.0M
$58.6M
Q4 24
$269.9M
$56.3M
Q3 24
$265.1M
$75.4M
Q2 24
$279.1M
$89.6M
Q1 24
$296.2M
$112.8M
Total Debt
EDIT
EDIT
STEM
STEM
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$57.4M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
EDIT
EDIT
STEM
STEM
Q4 25
$27.3M
$-249.4M
Q3 25
$13.5M
$-235.7M
Q2 25
$19.2M
$-214.1M
Q1 25
$62.4M
$-417.5M
Q4 24
$134.3M
$-398.4M
Q3 24
$175.6M
$-344.1M
Q2 24
$232.0M
$-203.2M
Q1 24
$294.4M
$371.6M
Total Assets
EDIT
EDIT
STEM
STEM
Q4 25
$186.5M
$308.9M
Q3 25
$201.8M
$362.6M
Q2 25
$210.6M
$379.2M
Q1 25
$263.7M
$405.1M
Q4 24
$341.6M
$437.4M
Q3 24
$327.6M
$537.8M
Q2 24
$384.8M
$691.5M
Q1 24
$440.3M
$1.3B
Debt / Equity
EDIT
EDIT
STEM
STEM
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.43×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EDIT
EDIT
STEM
STEM
Operating Cash FlowLast quarter
$-36.4M
$8.2M
Free Cash FlowOCF − Capex
$-36.4M
FCF MarginFCF / Revenue
-147.3%
Capex IntensityCapex / Revenue
0.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EDIT
EDIT
STEM
STEM
Q4 25
$-36.4M
$8.2M
Q3 25
$-30.8M
$11.4M
Q2 25
$-50.2M
$-21.3M
Q1 25
$-47.8M
$8.5M
Q4 24
$-50.8M
$-14.7M
Q3 24
$-52.6M
$-9.4M
Q2 24
$-57.1M
$-11.9M
Q1 24
$-49.9M
$-621.0K
Free Cash Flow
EDIT
EDIT
STEM
STEM
Q4 25
$-36.4M
Q3 25
$-31.3M
Q2 25
Q1 25
$-47.9M
Q4 24
$-51.3M
Q3 24
$-55.5M
Q2 24
$-60.6M
Q1 24
$-51.7M
FCF Margin
EDIT
EDIT
STEM
STEM
Q4 25
-147.3%
Q3 25
-414.6%
Q2 25
Q1 25
-1028.6%
Q4 24
-167.6%
Q3 24
-90998.4%
Q2 24
-11804.3%
Q1 24
-4558.9%
Capex Intensity
EDIT
EDIT
STEM
STEM
Q4 25
0.2%
Q3 25
5.7%
Q2 25
0.0%
Q1 25
2.4%
Q4 24
1.8%
Q3 24
4788.5%
Q2 24
681.1%
Q1 24
164.8%
Cash Conversion
EDIT
EDIT
STEM
STEM
Q4 25
Q3 25
Q2 25
-0.11×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons